|
AstraZeneca Buys Synairgen Asthma Drug For $7.25M
BioResearch Online (press release) AstraZeneca announced that it has signed into a global license agreement with Synairgen, a pharmaceutical company focused on respiratory disease, to buy SNG001, a novel immuno-modulatory therapy for viral-induced exacerbation in asthma. SNG001 is … |
View full post on asthma – Google News